1. Home
  2. PNI vs TENX Comparison

PNI vs TENX Comparison

Compare PNI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco New York Municipal Income Fund II of Beneficial Interest

PNI

Pimco New York Municipal Income Fund II of Beneficial Interest

N/A

Current Price

$6.83

Market Cap

76.8M

Sector

Finance

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.75

Market Cap

71.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PNI
TENX
Founded
2002
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.8M
71.1M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
PNI
TENX
Price
$6.83
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
46.5K
8.5M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
4.76%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.54
$1.31
52 Week High
$7.20
$19.40

Technical Indicators

Market Signals
Indicator
PNI
TENX
Relative Strength Index (RSI) 37.16 18.90
Support Level $6.64 $1.31
Resistance Level $7.07 $16.39
Average True Range (ATR) 0.05 0.35
MACD -0.00 -0.41
Stochastic Oscillator 11.11 3.04

Price Performance

Historical Comparison
PNI
TENX

About PNI Pimco New York Municipal Income Fund II of Beneficial Interest

PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: